Rani Therapeutics demonstrated that RT-114, an oral GLP-1/GLP-2 dual agonist delivered via RaniPill® capsule, achieved 111% bioavailability compared to subcutaneous injection in preclinical studies, with comparable weight loss outcomes.
Zealand Pharma reported positive Phase 1b results for petrelintide and dapiglutide, advancing both into Phase 2b trials for overweight and obese patients.